Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 212

Similar articles for PubMed (Select 9313020)

1.

Three methods of opioid detoxification in a primary care setting. A randomized trial.

O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ.

Ann Intern Med. 1997 Oct 1;127(7):526-30.

PMID:
9313020
2.

The Pain Reliever and Heroin Epidemic in the United States: Shifting Winds in the Perfect Storm.

Maxwell JC.

J Addict Dis. 2015 Jun 24:0. [Epub ahead of print]

PMID:
26106929
3.

"Sub is a weird drug:" A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms.

Daniulaityte R, Carlson R, Brigham G, Cameron D, Sheth A.

Am J Addict. 2015 May 25. doi: 10.1111/ajad.12213. [Epub ahead of print]

PMID:
26009867
4.

[The POISE-2 Clonidine trial].

Fumagalli S, Del Medico M, Montano N.

G Ital Cardiol (Rome). 2015 May;16(5):265-70. doi: 10.1714/1870.20420. Italian. No abstract available.

PMID:
25994460
5.

Baseline characteristics of patients predicting suitability for rapid naltrexone induction.

Mogali S, Khan NA, Drill ES, Pavlicova M, Sullivan MA, Nunes E, Bisaga A.

Am J Addict. 2015 Apr;24(3):258-64. doi: 10.1111/ajad.12180.

PMID:
25907815
6.

Characterizing opioid withdrawal during double-blind buprenorphine detoxification.

Dunn KE, Saulsgiver KA, Miller ME, Nuzzo PA, Sigmon SC.

Drug Alcohol Depend. 2015 Jun 1;151:47-55. doi: 10.1016/j.drugalcdep.2015.02.033. Epub 2015 Mar 12.

PMID:
25823907
7.

Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial.

Dakwar E, Kleber HD.

J Subst Abuse Treat. 2015 Jun;53:60-3. doi: 10.1016/j.jsat.2015.01.004. Epub 2015 Jan 15.

PMID:
25819700
8.

Clonidine Maintenance Prolongs Opioid Abstinence and Decouples Stress From Craving in Daily Life: A Randomized Controlled Trial With Ecological Momentary Assessment.

Kowalczyk WJ, Phillips KA, Jobes ML, Kennedy AP, Ghitza UE, Agage DA, Schmittner JP, Epstein DH, Preston KL.

Am J Psychiatry. 2015 Mar 17:appiajp201414081014. [Epub ahead of print]

PMID:
25783757
9.

[A randomized, double-blind, controlled study: Ji-Tai tablet for the treatment of acute withdrawl syndrome of mild heroin dependence].

Wang Y, Tang C, Cheng S, Cui G, Zhang R, Zhang Z, Xie L, Lin Y, Hao W.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2015 Feb;40(2):117-22. doi: 10.11817/j.issn.1672-7347.2015.02.001. Chinese.

10.

Subjective effects of prisoners using buprenorphine for detoxification.

Johnstone A, Duffy T, Martin C.

Int J Prison Health. 2011;7(4):52-65. doi: 10.1108/17449201111256907.

PMID:
25757712
11.

Comparative trial to study the effectiveness of clonidine hydrochloride and buprenorphine-naloxone in opioid withdrawal - a hospital based study.

Hussain SS, Farhat S, Rather YH, Abbas Z.

J Clin Diagn Res. 2015 Jan;9(1):FC01-4. doi: 10.7860/JCDR/2015/10625.5425. Epub 2015 Jan 1.

12.

Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone.

Rodgman CJ, Verrico CD, Worthy RB, Lewis EE.

Prim Care Companion CNS Disord. 2014 Aug 14;16(4). doi: 10.4088/PCC.13l01594. eCollection 2014. No abstract available.

13.

Extended release naltrexone for alcohol use disorders: quasi-experimental effects on mortality and subsequent detoxification episodes.

Harris AH, Bowe T, Del Re AC, Finlay AK, Oliva E, Myrick HL, Rubinsky AD.

Alcohol Clin Exp Res. 2015 Jan;39(1):79-83. doi: 10.1111/acer.12597.

PMID:
25623408
14.

Challenges in the perioperative management of the patient receiving extended-release naltrexone.

Curatolo C, Trinh M.

A A Case Rep. 2014 Dec 1;3(11):142-4. doi: 10.1213/XAA.0000000000000069.

PMID:
25612099
15.

Amantadine as Augmentation in Managing Opioid Withdrawal with Clonidine: a randomized controlled trial.

Amiri S, Malek A, Tofighnia F, Habibi Asl B, Seidy A.

Iran J Psychiatry. 2014 Jul;9(3):142-6.

16.

Baseline characteristics of patients predicting suitability for rapid naltrexone induction.

Mogali S, Khan NA, Drill ES, Pavlicova M, Sullivan MA, Nunes E, Bisaga A.

Am J Addict. 2014 Dec 30. doi: 10.1111/j.1521-0391.2014.12180.x. [Epub ahead of print]

PMID:
25556773
17.

Opioid use and dropout in patients receiving oral naltrexone with or without single administration of injection naltrexone.

Sullivan MA, Bisaga A, Glass A, Mishlen K, Pavlicova M, Carpenter KM, Mariani JJ, Levin FR, Nunes EV.

Drug Alcohol Depend. 2015 Feb 1;147:122-9. doi: 10.1016/j.drugalcdep.2014.11.028. Epub 2014 Dec 9.

PMID:
25555621
18.

Predictors of dropout from inpatient opioid detoxification with buprenorphine: a chart review.

Hakansson A, Hallén E.

J Addict. 2014;2014:965267. doi: 10.1155/2014/965267. Epub 2014 Oct 30.

19.

Lifetime history of heroin use is associated with greater drug severity among prescription opioid abusers.

Meyer AC, Miller ME, Sigmon SC.

Addict Behav. 2015 Mar;42:189-93. doi: 10.1016/j.addbeh.2014.11.006. Epub 2014 Nov 18.

PMID:
25481453
20.

The Severity, Frequency, and Variety of Crime in Heroin-Dependent Prisoners Enrolled in a Buprenorphine Clinical Trial.

Gordon MS, Kinlock TW, Schwartz RP, Couvillion KA, O'Grady KE.

Prison J. 2013 Dec 1;93(4):390-410.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk